News

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

Funding raised to accelerate and expand cell therapy pipeline.

Three world leaders in science and entrepreneurship appointed to bit.bio's Board of Directors.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.

Press release announcing appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer.

bit.bio joins forces with London institute of mathematical sciences to find the ‘operating system of life’.

bit.bio closes series A $41.5 million funding.

Bit Bio announces agreement with Abcam, to make Bit Bio’s iPSC derived functional human cells widely available.